CLINICAL TRIALS PROFILE FOR LURBINECTEDIN
✉ Email this page to a colleague
All Clinical Trials for Lurbinectedin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01314599 ↗ | Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome | Completed | PharmaMar | Phase 1 | 2011-05-01 | Phase I Study of PM01183 in Patients with Advanced Acute Leukemia to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183. |
| NCT01831089 ↗ | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | Completed | PharmaMar | Phase 1 | 2013-09-01 | Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors |
| NCT01951157 ↗ | A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients | Completed | PharmaMar | Phase 2 | 2013-09-11 | A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients |
| NCT01980667 ↗ | Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors | Completed | PharmaMar | Phase 1 | 2014-07-30 | Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Cisplatin in Patients with Advanced Solid Tumors to determine the recommended dose (RD) of PM01183 in combination with cisplatin, to characterize the safety profile, the pharmacokinetics (PK) of this combination, to obtain preliminary information on the clinical antitumor activity and to conduct an exploratory pharmacogenomic (PGx) analysis. |
| NCT02210364 ↗ | Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). | Completed | PharmaMar | Phase 1 | 2013-04-01 | Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Capecitabine in Patients with Unresectable Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC) to determine the recommended dose (RD) of PM01183 in combination with capecitabine, to characterize the safety profile, to explore the feasibility of PM01183 dose optimization, to characterize the pharmacokinetics (PK), to obtain preliminary information on the clinical antitumor activity of this combination and to conduct an exploratory pharmacogenomic (PGx) analysis. |
| NCT02421588 ↗ | Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients | Completed | PharmaMar | Phase 3 | 2015-05-01 | Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer. PM01183 will be explored as single agent in the experimental arm (Arm A) versus PLD or topotecan in the control arm (Arm B). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Lurbinectedin
Condition Name
Clinical Trial Locations for Lurbinectedin
Trials by Country
Clinical Trial Progress for Lurbinectedin
Clinical Trial Phase
Clinical Trial Sponsors for Lurbinectedin
Sponsor Name
